Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Filmmaker Moore's Look At Pharma On Backburner?

This article was originally published in The Pink Sheet Daily

Executive Summary

Michael Moore's plans for a Fahrenheit 9/11 sequel in time for the next presidential race may delay work on Sicko, his expected documentary on the U.S. health care system. The film is understood to remain in the earliest stages of development due to an absence of financial backing.

You may also be interested in...



Michael Moore Gives Sicko New Life

Filmmaker has heightened his focus on a documentary looking at the American health care system, including the drug industry. Handicapping of Fahrenheit 9/11's chances in the Oscar race appears to be one factor behind renewing work on the project.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel